390 related articles for article (PubMed ID: 22562529)
1. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly.
Niculescu D; Purice M; Coculescu M
Pituitary; 2013 Jun; 16(2):168-74. PubMed ID: 22562529
[TBL] [Abstract][Full Text] [Related]
2. Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels.
Mori K; Iwasaki Y; Kawasaki-Ogita Y; Honjo S; Hamamoto Y; Tatsuoka H; Fujimoto K; Ikeda H; Wada Y; Takahashi Y; Takahashi J; Koshiyama H
J Endocrinol Invest; 2013 Nov; 36(10):853-9. PubMed ID: 23665535
[TBL] [Abstract][Full Text] [Related]
3. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
4. Correlation analysis between short-term insulin-like growth factor-I and glucose intolerance status after transsphenoidal adenomectomy in acromegalic patients: a large retrospective study from a single center in China.
Li YL; Zhang S; Guo XP; Gao L; Lian W; Yao Y; Deng K; Wang RZ; Xing B
Arch Endocrinol Metab; 2019; 63(2):157-166. PubMed ID: 30916168
[TBL] [Abstract][Full Text] [Related]
5. [Lowered ghrelin levels in acromegaly—normalization after treatment].
Kozakowski J; Rabijewski M; Zgliczyński W
Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
[TBL] [Abstract][Full Text] [Related]
6. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
7. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly.
Dobrashian RD; O'Halloran DJ; Hunt A; Beardwell CG; Shalet SM
Clin Endocrinol (Oxf); 1993 Jun; 38(6):589-93. PubMed ID: 8334745
[TBL] [Abstract][Full Text] [Related]
8. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
9. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
10. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
Serri O; Beauregard C; Hardy J
J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
[TBL] [Abstract][Full Text] [Related]
11. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly.
Puder JJ; Nilavar S; Post KD; Freda PU
J Clin Endocrinol Metab; 2005 Apr; 90(4):1972-8. PubMed ID: 15634715
[TBL] [Abstract][Full Text] [Related]
12. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
Freda PU; Post KD; Powell JS; Wardlaw SL
J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
[TBL] [Abstract][Full Text] [Related]
14. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
15. Gender and age in the biochemical assessment of cure of acromegaly.
Freda PU; Landman RE; Sundeen RE; Post KD
Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
[TBL] [Abstract][Full Text] [Related]
16. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
[TBL] [Abstract][Full Text] [Related]
17. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
Freda PU; Nuruzzaman AT; Reyes CM; Sundeen RE; Post KD
J Clin Endocrinol Metab; 2004 Feb; 89(2):495-500. PubMed ID: 14764751
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly.
Freda PU; Bruce JN; Reyes-Vidal C; Singh S; DeLeon Y; Jin Z; Khandji AG; Cremers S; Post KD
Pituitary; 2021 Apr; 24(2):170-183. PubMed ID: 33124000
[TBL] [Abstract][Full Text] [Related]
19. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery.
Damjanović SS; Petakov MS; Raicević S; Micić D; Marinković J; Dieguez C; Casanueva FF; Popović V
J Clin Endocrinol Metab; 2000 Jan; 85(1):147-54. PubMed ID: 10634378
[TBL] [Abstract][Full Text] [Related]
20. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
